Searched for
LILLY NEUROSCIENCE
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley dealEli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental...- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow TuckerEli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant...
- Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatmentThe joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to...
- Eli Lilly pops patent pep pill, to launch latest drugsEncouraged by the introduction of the product patent regime, US-based Eli Lilly & Company is planning to introduce a range of new drugs in ...
Load More